A. Salud

Prospective Biomarker Study in Advanced RAS Wild‐Type Colorectal Cancer: POSIBA Trial (GEMCAD 10‐02)

F. Rojo, J. Feliu, J. Maurel, 2019, The oncologist.

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.

G. Capellá, R. Salazar, D. Páez, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

A. Carrato, R. Salazar, C. García-Girón, 2021, Drugs & Aging.

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients

F. Rojo, J. Feliu, J. Maurel, 2018, Neoplasia.

599PA VALIDATION OF CURRENT PROGNOSTIC SCORES IN METASTATIC COLORECTAL CANCER (MCRC) AND A NEW PROGNOSTIC SCORE (A GEMCAD STUDY).

J. Feliu, J. Maurel, M. Safont, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial.

Gina Brown, J. Aparicio, J. Feliu, 2012 .

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

F. Rivera, V. Arrazubi, P. Jiménez-Fonseca, 2019, Cancer Chemotherapy and Pharmacology.

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

A. Carrato, E. Polo, E. Grande, 2019, BMC Cancer.

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.

E. Polo, M. Valladares-Ayerbes, F. Rivera, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials.

M. Guillot, M. Valladares-Ayerbes, F. Rivera, 2023, Clinical colorectal cancer.

Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (LA) or metastatic colorectal cancer (MCRC).

C. García-Girón, F. Rivera, C. Martín, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.